News

Marlborough, Mass.-based Sunovion Pharmaceuticals is supporting several advocacy initiatives during the month of November in observance of the coinciding Chronic Obstructive Pulmonary Disease (COPD) and Epilepsy Awareness Months in the U.S., as well as World COPD Day on Nov. 16. Sunovion, a wholly owned subsidiary of Sumitomo Dainippon Pharma…

The Aerobika device, developed by Monaghan Medical Corporation (MMC), is effective in reducing drug use and costs for patients with chronic obstructive pulmonary disease (COPD), according to a presentation at the recent American College of Chest Physicians (CHEST) annual meeting in Los Angeles. The Aerobika Oscillating Positive Expiratory Pressure (OPEP),…

The American College of Chest Physicians (CHEST) and Sunovion presented their new joint initiative called Delivery Makes a Difference at the CHEST 2016 Annual Meeting Oct. 22-26 in Los Angeles. Delivery Makes a Difference aims to increase awareness about the importance of drug delivery systems for diseases such as chronic obstructive pulmonary…

Theravance Biopharma and Mylan recently reported positive Phase 3 trial data on the effectiveness of the drug revefenacin (TD-4208) for the treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is an investigational long-acting muscarinic antagonist (LAMA) and the first once-daily nebulized bronchodilator in development to treat COPD. The drug will be…

The FDA recently accepted a New Drug Application (NDA) for Sunovion’s investigational treatment SUN-101 (glycopyrrolate) administered by the eFlow nebulizer to treat adults with chronic obstructive pulmonary disease (COPD). Although the FDA’s acceptance of the NDA for review does not guarantee approval, it is a crucial step in the drug approval process. Sunovian…

People with very mild chronic obstructive pulmonary disease (COPD) show severe loss of lung function after an acute flare, a new study reported, suggesting that drugs to prevent exacerbations may need to be considered to slow disease progression in these patients. But the study, “Acute Exacerbations and Lung Function…

Boehringer Ingelheim Pharmaceuticals and Ashfield Healthcare have launched a new and free patient support program. Called ‘STIOLTO Promise,’ the no-cost offer provides 30 days of medicine, resources, and at-home counseling via respiratory specialists for patients with chronic obstructive pulmonary disease (COPD) who are prescribed STIOLTO RESPIMAT. STIOLTO RESPIMAT was approved in May 2015 for…

ResApp Health, an Australian company developing digital healthcare solutions for respiratory conditions, recently reported additional preliminary positive results of its adult clinical trial assessing the company’s app for the diagnosis of different lung diseases, including chronic obstructive pulmonary fibrosis (COPD). According to a ResApp press release, the results showed that the…

A new research study suggests that high indoor temperatures could worsen the symptoms of chronic obstructive pulmonary disease (COPD), particularly in homes with high levels of air pollutants. Johns Hopkins University researchers conducted a longitudinal study including 69 patients with moderate-to-severe COPD during the hottest days of the year. The results of…

A component of red wine and grapes, resveratrol, was seen to halt the pathogen-induced inflammation common in respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The study, “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short,” was published in the online…